Albert Bourla, CEO of Pfizer, joins 'Money Movers' to discuss drug pricing, the impact on artificial intelligence on ...

According to reporting from Bloomberg at the J.P. Morgan Healthcare Conference that ended today in San Francisco, ...

Big pharma is grappling with new drug pricing deals and roughly $300 billion in potential lost revenue from patent ...

When Albert Bourla became CEO of Pfizer in 2019, just before the pandemic, he wanted to make Pfizer’s medicines more affordable to more patients. But COVID-19 delayed those plans when Bourla decided ...

Albert Bourla said Pfizer has discussed a fast-pass voucher with the White House during the JPMorgan Healthcare Conference.

Pharmaceutical companies seek to make up lost revenue after striking deals with Donald Trump to lower costs in US ...

Pfizer is gearing up for a consumer-driven obesity drug market, drawing parallels to the demand surge it experienced with the ...

U.S. pharmaceutical companies are stepping up their campaign for higher drug prices in Europe, in some cases threatening to ...

Pfizer is gearing up for a major push into the obesity drug market, drawing parallels to its success with Viagra. Despite ...

Matthew Herper covers medical innovation — both its promise and its perils. Pfizer CEO Albert Bourla on Wednesday defended the development of Covid vaccinations, including Pfizer’s own, suggesting ...

Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted ...